S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NASDAQ:ALEC

Alector (ALEC) Stock Price, News & Analysis

$7.41
+0.44 (+6.31%)
(As of 03/1/2024 ET)
Today's Range
$7.05
$7.57
50-Day Range
$5.69
$8.08
52-Week Range
$3.66
$9.06
Volume
1.64 million shs
Average Volume
656,875 shs
Market Capitalization
$709.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Alector MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
95.7% Upside
$14.50 Price Target
Short Interest
Bearish
7.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.60mentions of Alector in the last 14 days
Based on 32 Articles This Week
Insider Trading
Selling Shares
$185,926 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.87) to ($2.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.85 out of 5 stars

Medical Sector

241st out of 950 stocks

Biological Products, Except Diagnostic Industry

35th out of 151 stocks


ALEC stock logo

About Alector Stock (NASDAQ:ALEC)

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Stock Price History

ALEC Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Alector (NASDAQ:ALEC) Receives Buy Rating from HC Wainwright
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Alector to Participate in Upcoming Healthcare Conferences
TD Cowen Sticks to Their Buy Rating for Alector (ALEC)
Recap: Alector Q4 Earnings
Earnings Outlook For Alector
Here's what to expect from Alector's earnings
Alector (ALEC) Scheduled to Post Earnings on Tuesday
ALEC Mar 2024 7.500 call
Alector’s Promising Pipeline and Market Potential Affirm Buy Rating
GSK Feb 2024 42.000 put
See More Headlines
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/02/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
246
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$14.50
High Stock Price Target
$41.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+95.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-133,310,000.00
Net Margins
-134.34%
Pretax Margin
-128.97%

Debt

Sales & Book Value

Annual Sales
$97.06 million
Book Value
$1.40 per share

Miscellaneous

Free Float
82,344,000
Market Cap
$709.51 million
Optionable
Optionable
Beta
0.81

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Arnon Rosenthal Ph.D. (Age 68)
    Co-Founder, CEO & Director
    Comp: $1.02M
  • Dr. Sara Kenkare-Mitra Ph.D. (Age 56)
    President and Head of Research & Development
    Comp: $1.19M
  • Dr. Marc Grasso M.D. (Age 51)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $738.05k
  • Dr. Gary Romano M.D. (Age 62)
    Ph.D., Chief Medical Officer
    Comp: $602.98k
  • Mr. Peter Heutink Ph.D.
    Chief Scientific Officer
  • Katie Hogan
    Senior Director of Corporate Communication & Investor Relations
  • Ms. Danielle Pasqualone J.D.
    Ph.D., General Counsel
  • Ms. Clare Hunt M.B.A.
    Chief People Officer
  • Ms. Kristina Cutter M.P.H.
    Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
  • Ms. Virginia DeJesus-Rueff M.B.A.
    Chief of Staff & Head of Strategy














ALEC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alector stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALEC shares.
View ALEC analyst ratings
or view top-rated stocks.

What is Alector's stock price target for 2024?

7 brokerages have issued 1 year price targets for Alector's shares. Their ALEC share price targets range from $4.00 to $41.00. On average, they expect the company's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 95.7% from the stock's current price.
View analysts price targets for ALEC
or view top-rated stocks among Wall Street analysts.

How have ALEC shares performed in 2024?

Alector's stock was trading at $7.98 on January 1st, 2024. Since then, ALEC shares have decreased by 7.1% and is now trading at $7.41.
View the best growth stocks for 2024 here
.

When is Alector's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALEC earnings forecast
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) released its quarterly earnings results on Thursday, November, 4th. The company reported $1.49 EPS for the quarter, beating the consensus estimate of ($0.46) by $1.95. The business earned $182.41 million during the quarter, compared to analysts' expectations of $407.41 million. Alector had a negative trailing twelve-month return on equity of 77.15% and a negative net margin of 134.34%.

What ETF holds Alector's stock ?

iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

What guidance has Alector issued on next quarter's earnings?

Alector updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $60.0 million-$70.0 million, compared to the consensus revenue estimate of $100.9 million.

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Who are Alector's major shareholders?

Alector's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.62%), Braidwell LP (3.50%), Price T Rowe Associates Inc. MD (1.26%), Price T Rowe Associates Inc. MD (1.26%), Dimensional Fund Advisors LP (0.80%) and Northern Trust Corp (0.65%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends
.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alector have any subsidiaries?
The following companies are subsidiares of Alector: Alector LLC.
Read More
This page (NASDAQ:ALEC) was last updated on 3/3/2024 by MarketBeat.com Staff